Development of a patient-reported outcome (PRO) instrument to assess complex activities of daily living and interpersonal functioning in patients with mild cognitive impairment due to suspected Alzheimer’s disease: the qualitative research phase
The advantages of frontotemporal degeneration drug development (Part 2 of frontotemporal degeneration: the next therapeutic frontier)
Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium
Understanding Placebo Responses in Alzheimer’s Disease Clinical Trials from the Literature Meta-Data and CAMD Database
C-Path Cosponsors Workshop on Combination Drug Development for Alzheimer’s Disease Combination therapy development has been successful in other life-threatening diseases in part because collaborative approaches we
January 10, 2012 Combining Patient-level And Summary-level Data For Alzheimer’s Disease Modeling And Simulation: A Β Regression Meta-analysis
Stakeholders Share Data to Design Better Trials for Neurodegenerative Diseases The Coalition Against Major Diseases is pooling clinical data to build disease and drug models.
